A diterpene geranylgeraniol suppressed the viability of human DU145 prostate carcinoma cells by arresting cell cycle at the G1 phase and initiating apoptosis. This tumor-suppressive activity of geranylgeraniol was accompanied by a concentration-dependent down-regulation of HMG CoA reductase, a key enzyme in the mevalonate pathway that provides essential intermediates required for growth. Geranylgeraniol may be a new weapon in the arsenal of mevalonate-suppressive isoprenoids with potential synergism in the fight against prostate cancer.
↧